Quinn Emanuel has secured a pivotal patent ruling for client The Broad Institute, Inc. (“Broad”) in a proceeding involving The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier (“CVC”). On Monday, February 28, 2022, a three-judge panel of the Patent Trial and Appeal Board (“PTAB”) issued an opinion and judgment confirming Broad’s entitlement to foundational patents directed to the use of CRISPR-Cas9 in eukaryotic cells (including humans, other mammals, and plants).
CRISPR-Cas9 is a revolutionary technology that provides the ability to precisely edit the genome of living cells, and holds enormous potential to accelerate life science research, improve biotechnology, and diagnose and treat human disease.
Broad was represented by a Quinn Emanuel team including Ray Nimrod, who served as lead counsel, Matthew D. Robson, and Zach Summers, along with co-counsel.
The ruling was covered widely in the press, including in the following:
- Crispr Patent Ruling Picks Winners in Dispute Over Gene-Editing Technology, The Wall Street Journal
- Crispr Ruling Invalidates Some Biotech Company Patents, Bloomberg
- Broad Institute, MIT Win Patent Battle Over CRISPR, Law360
- Breakthrough gene-editing technology belongs to Harvard, MIT -U.S. tribunal, Reuters
- CRISPR Ruling Invalidates Some Biotech Company Patents, Time
- Quinn Emanuel Gets a Vital Win on Gene-Editing Patents at the PTAB, The American Lawyer